{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:59:47Z","timestamp":1791377987895,"version":"4.3.2"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"ARCO (Associazione Ricerche e Cure in Oncologia)"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffman\u2013La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merk Serono"},{"name":"Sirtex"},{"DOI":"10.13039\/100007013","name":"F. Hoffman\u2013La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Serono"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T06:04:44Z","timestamp":1549778684000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial"],"prefix":"10.1016","volume":"110","author":[{"given":"Gianluca","family":"Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-2326","authenticated-orcid":false,"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-5904","authenticated-orcid":false,"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Buccianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Sainato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Damiano","family":"Luca Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fontanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Musettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Montrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pasqualetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2019.01.006_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017. CA","volume":"67","author":"Siegel","year":"2017","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.ejca.2019.01.006_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt240","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Glimelius","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.01.006_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-017-0964-8","article-title":"Controversies in the multimodality management of locally advanced rectal cancer","author":"D\u00edaz Beveridge","year":"2017","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.006_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.25.8541","volume":"28","author":"Fern\u00e1ndez-Martos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.006_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","article-title":"Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial","volume":"11","author":"Chua","year":"2010","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2019.01.006_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2019.01.006_bib7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.01.006_bib8","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2006.08.007","article-title":"Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice","author":"Willett","year":"2006","journal-title":"Semin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2019.01.006_bib9","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.3748\/wjg.v20.i20.6081","article-title":"Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review","volume":"20","author":"Fornaro","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"8514","key":"10.1016\/j.ejca.2019.01.006_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0140-6736(86)92612-7","article-title":"Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision","volume":"328","author":"Quirke","year":"1986","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.006_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Dis"},{"issue":"8","key":"10.1016\/j.ejca.2019.01.006_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.01.006_bib13","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170125155530","article-title":"Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase","author":"Re","year":"2017","journal-title":"Curr Pharmaceut Des"},{"issue":"20","key":"10.1016\/j.ejca.2019.01.006_bib14","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2007.15.9426","article-title":"Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin","volume":"26","author":"Hennig","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.006_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","article-title":"The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia","volume":"14","author":"Di Paolo","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ejca.2019.01.006_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2015.02.001","article-title":"Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer","author":"Valentini","year":"2015","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2019.01.006_bib17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.01.006_bib18","first-page":"369","article-title":"Pretreatment serum folate levels and toxicity\/efficacy in colorectal cancer patients treated with 5-fluorouracil and folinic acid","volume":"15","author":"Yan","year":"2016","journal-title":"Clin Colorectal Canc"},{"issue":"6","key":"10.1016\/j.ejca.2019.01.006_bib19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","article-title":"Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety","volume":"27","author":"Luo","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.006_bib20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1634\/theoncologist.2010-0285","article-title":"Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study","volume":"16","author":"Nogu\u00e9","year":"2011","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.006_bib21","first-page":"24","article-title":"Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study","volume":"38","author":"Yu","year":"2018","journal-title":"Cancer Commun (London, England)"},{"issue":"13","key":"10.1016\/j.ejca.2019.01.006_bib22","doi-asserted-by":"crossref","first-page":"e6487","DOI":"10.1097\/MD.0000000000006487","article-title":"Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer","volume":"96","author":"Zheng","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"7","key":"10.1016\/j.ejca.2019.01.006_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2019.01.006_bib24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","article-title":"Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.006_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 ? 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.01.006_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","article-title":"Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial","volume":"32","author":"Schrag","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.01.006_bib27","series-title":"Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery - Full Text View \u2013 ClinicalTrials.gov","author":"PROSPECT","year":"2012"},{"issue":"7","key":"10.1016\/j.ejca.2019.01.006_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/DCR.0000000000000849","article-title":"Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial","volume":"60","author":"Rouanet","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejca.2019.01.006_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2018.09.006","article-title":"FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: results of the FFCD 1102 phase II trial","volume":"104","author":"Bachet","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2019.01.006_bib30","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1245\/s10434-010-0972-9","article-title":"Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX\/FOLFOX","volume":"17","author":"Klinger","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.01.006_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw052","article-title":"FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials","volume":"27","author":"Cremolini","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2019.01.006_bib32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.01.006_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.006_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2010.08.005","article-title":"Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer","volume":"82","author":"Dipetrillo","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2019.01.006_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/cam4.1298","article-title":"The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis","volume":"7","author":"Zhong","year":"2018","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.ejca.2019.01.006_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e00804","article-title":"BACCHUS: a randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)","volume":"4","author":"Glynne-Jones","year":"2018","journal-title":"Heliyon"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:53Z","timestamp":1762342493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919300188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"alternative-id":["S0959804919300188"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}